Drug Updates

Hansa Biopharma Reaches Milestone in Pursuit of Innovative GBS Treatment with Imlifidase

Hansa Biopharma (Nasdaq Stockholm: HNSA), an enzyme technology pioneer focused on transforming the lives of those with rare immunological disorders, proudly announces the completion of enrollment in its groundbreaking phase 2 clinical trial for imlifidase in Guillain-Barré Syndrome (GBS). The top-line findings from this study are slated for release in late 2023. Søren Tulstrup, the […]